



## INDUSTRY SESSION PROGRAMMES



Lilly

abbvie

SANOFI GENZYME REGENERON

NOVARTIS



janssen Immunology  
PHARMACEUTICAL COMPANIES OF

GALDERMA

Pfizer

almirall

L'ORÉAL DERMATOLOGICAL BEAUTY  
 LA ROCHE-POSAY CeraVe VICHY

Pierre Fabre  
DERMATOLOGIE

AMGEN®

Bristol Myers Squibb™

Boehringer  
Ingelheim

Eucerin®  
LIFE-CHANGING POWER OF  
DERMATOLOGICAL SKINCARE

Incyte

AMRYT  
PHARMA

SiHEALTH  
Sensing & Intelligence for HealthCare

BELLA AURORA  
LABS

sofwave™

BRITISH ASSOCIATION  
OF DERMATOLOGISTS  
HEALTHY SKIN FOR ALL

Medscape  
EDUCATION GLOBAL

Quality of  
Care in AD

Med Learning Group | UMA  
A DIVISION OF ULTIMATE MEDICAL ACADEMY

medthority  
Personalised to support your treatment decisions



## TABLE OF CONTENTS

<b>INDUSTRY SESSION PROGRAMMES .....</b>	1
<b>VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE .....</b>	6
<b>Satellite Symposia.....</b>	6
Wednesday 29 September 2021 .....	6
<b>VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE .....</b>	7
<b>Satellite Symposia.....</b>	7
Thursday 30 September 2021 .....	7
<b>VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE .....</b>	8
<b>Satellite Symposia.....</b>	8
Friday 01 October 2021 .....	8
<b>VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE .....</b>	9
<b>Satellite Symposia.....</b>	9
Saturday 02 October 2021.....	9
<b>VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE .....</b>	10
<b>Industry HUB .....</b>	10
<b>INDUSTRY SESSION PROGRAMME AND FACULTY IN PARTICULAR.....</b>	11
<b>ACCESS TO INDUSTRY SESSIONS AND REGULATIONS RELATED TO INDUSTRY ACTIVITIES.....</b>	11

### **SATELLITE SYMPOSIA – Wednesday 29 September 2021**

SAT 10 - Vichy Laboratoires.....	12
SAT 23 - Eucerin by BEIERSDORF .....	13
SAT 24 - Bella Aurora Labs.....	13
SAT 25 - Amryt Pharma DAC.....	14
SAT 36 - Novartis .....	14
SAT 37 - Janssen .....	15
SAT 38 - L'Oréal - La Roche-Posay .....	16
SAT 39 - Sanofi Genzyme & Regeneron.....	17
SAT 40 - Lilly.....	17
SAT 41 - CeraVe .....	18
SAT 42 - Bristol Myers Squibb.....	18
SAT 44 - Amgen.....	19



SAT 51 - Sanofi Genzyme & Regeneron.....	20
SAT 57 - Sanofi Genzyme & Regeneron.....	21
SAT 58 - Sanofi Genzyme & Regeneron.....	21
SAT 59 - Medscape – Supported by an independent educational grant from Janssen .....	22

#### **SATELLITE SYMPOSIA – Thursday 30 September 2021**

SAT 61 - Galderma .....	23
SAT 62 - Almirall.....	23
SAT 63 - Incyte Biosciences International Sàrl.....	24
SAT 64 - Medscape – Supported by an independent educational grant from Lilly.....	24
SAT 74 - Lilly.....	25
SAT 75 - Sanofi Genzyme & Regeneron.....	25
SAT 76 - AbbVie .....	26
SAT 77 - Medscape – Supported by an independent educational grant from UCB Pharma, Inc .....	26
SAT 78 - Pfizer.....	27
SAT 79 - LEO Pharma .....	27
SAT 80 - Galderma .....	28
SAT 82 - Bristol Myers Squibb.....	28
SAT 83 - Medthority .....	29
SAT 84 - AbbVie .....	29
SAT 85 - Sanofi Genzyme .....	30
SAT 86 - Med Learning Group on behalf of Regeneron Pharmaceuticals, Inc and Sanofi Genzyme .....	30
SAT 87 - Janssen .....	31
SAT 88 - Galderma .....	31
SAT 89 - Almirall.....	32

#### **INDUSTRY HUB – Thursday 30 September 2021**

HUB 1.03 - L'Oréal Paris.....	33
HUB 1.04 - Amgen .....	33
HUB 1.05 - Sofwave .....	34
HUB 1.06 - L'Oréal - La Roche-Posay .....	34
HUB 1.07 - CeraVe .....	35
HUB 2.01 - Galderma .....	35



HUB 2.02 - PIERRE FABRE DERMATOLOGIE.....	36
HUB 2.03 - LEO Pharma .....	36
HUB 2.04 - UCB .....	37
HUB 2.05 - Almirall .....	38
HUB 2.06 - Janssen .....	39
HUB 2.07 - UCB .....	39

#### **SATELLITE SYMPOSIA – Friday 01 October 2021**

SAT 95 - Galderma .....	40
SAT 108 - Novartis .....	40
SAT 109 - AbbVie .....	41
SAT 110 - Sanofi Genzyme & Regeneron.....	41
SAT 111 - UCB .....	42
SAT 112 - Pfizer.....	42
SAT 113 - Galderma .....	43
SAT 114 - Almirall .....	43
SAT 115 - LABORATOIRES DERMATOLOGIQUES AVENE.....	44
SAT 117 - AbbVie .....	45
SAT 118 - Sanofi Genzyme & Regeneron.....	46
SAT 119 - Janssen .....	46
SAT 120 - Galderma .....	47
SAT 121 - Boehringer Ingelheim International GmbH.....	47

#### **INDUSTRY HUB – Friday 01 October 2021**

HUB 1.08 - L'Oréal - La Roche-Posay .....	48
HUB 1.09 - siHealth.....	48
HUB 1.11 - Vichy Laboratoires.....	49
HUB 1.12 - Pfizer.....	49
HUB 1.13 - CeraVe .....	50
HUB 1.14 - British Association of Dermatologists (BAD) .....	50
HUB 2.08 - Galderma .....	51
HUB 2.10 - LEO Pharma .....	51
HUB 2.11 - Janssen .....	52
HUB 2.12 - LEO Pharma .....	53



HUB 2.13 - LEO Pharma .....	54
HUB 2.14 - UCB .....	54

#### **SATELLITE SYMPOSIA – Saturday 02 October 2021**

SAT 151 - Boehringer Ingelheim International GmbH .....	55
---	----

#### **INDUSTRY HUB – Saturday 02 October 2021**

HUB 2.16 - UCB .....	56
HUB 2.18 - Galderma .....	56
HUB 2.19 - LEO Pharma .....	57



## VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE

### Satellite Symposia

**Wednesday 29 September 2021**

Access restricted to Health Care Professionals Only    Access Open to All

Room name		Room 1	Room 2	Room 3	Room 4	Room 5	Room 6	Room 7	Room 8	Room 9	Room 10	Room 11	Room 12	Room 13
Capacity		Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited
<b>Wednesday 29 September 2021</b>														
Morning Slots 1  10:00-11:00	Session Code	SAT10												
	Presentation: 10:00-11:00	Vichy Laboratoires												
Morning Slots 2  11:30-12:30	Session Code	SAT23	SAT24	SAT25										
	Presentation: 11:30-12:30	Eucerin by BEIERSDORF	Bella Aurora Labs	Amryt Pharma DAC										
Lunch Slots  13:00-14:00	Session Code	SAT36	SAT37	SAT38	SAT39									
	Presentation: 13:00-14:00	Novartis	Janssen	L'Oréal - La Roche-Posay	Sanofi Genzyme & Regeneron									
Afternoon Slots 1  14:30-15:30	Session Code										SAT40	SAT41	SAT42	
	Presentation: 14:30-15:30										Lilly	CeraVe	Bristol Myers Squibb	
Afternoon Slots 2  15:45-16:45	Session Code										SAT44			
	Presentation: 15:45-16:45										Amgen			
Evening Slots  17:00-18:30	Session Code	SAT57	SAT58	SAT59	SAT51									
	Presentation: 17:00-18:00	Sanofi Genzyme & Regeneron	Sanofi Genzyme & Regeneron	Medscape – Supported by Janssen	Sanofi Genzyme & Regeneron									
	Extended Presentation: 17:00-18:30													



## VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE

### Satellite Symposia

Thursday 30 September 2021



Access restricted to Health Care Professionals Only



Access Open to All

Room name		Room 1	Room 2	Room 3	Room 4	Room 5	Room 6	Room 7	Room 8	Room 9	Room 10	Room 11	Room 12	Room 13
Capacity		Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited
Thursday 30 September 2021														
Morning Slots  08:30-09:30	Session Code	SAT61	SAT62	SAT63	SAT64	Incyte Biosciences International Sàrl  Presentation: 08:30-09:30	Medscape – Supported by an independent educational grant from Lilly.	Galderma	Almirall					
	Presentation: 08:30-09:30	Galderma	Almirall	Incyte Biosciences International Sàrl	Presentation: 08:30-09:30	Medscape – Supported by an independent educational grant from Lilly.	Galderma	Almirall						
Lunch Slots  13:00-14:00	Session Code	SAT74	SAT75	SAT76	SAT77	SAT78	SAT79	SAT80	SAT82	Bristol Myers Squibb				
	Presentation: 13:00-14:00	Lilly	Sanofi Genzyme & Regeneron	AbbVie	Pfizer	Leo Pharma	Galderma		Bristol Myers Squibb					
Evening Slots  18:00-19:30	Session Code	Medthority	SAT83	SAT84	SAT85	SAT86	SAT87	SAT88	SAT89	Almirall	Janssen	Galderma		
	Presentation: 18:00-19:00													
	Extended Presentation: 19:00-19:30													



## VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE

### Satellite Symposia

**Friday 01 October 2021**



Access restricted to Health Care Professionals Only



Access Open to All

Room name		Room 1	Room 2	Room 3	Room 4	Room 5	Room 6	Room 7	Room 8	Room 9	Room 10	Room 11	Room 12	Room 13
Capacity		Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited
Friday 01 October 2021														
Morning Slots  08:30-09:30	Session Code	SAT95												
	Presentation: 08:30-09:30	Galderma	/	/	/	/	/	/	/	/	/	/	/	/
Lunch Slots  13:00-14:00	Session Code	SAT108	SAT109	SAT110	SAT111	SAT112	SAT113	SAT114	SAT115					
	Presentation: 13:00-14:00	Novartis	AbbVie	Sanofi Genzyme & Regeneron	UCB	Pfizer	Galderma	Almirall	LABORATOIRES DERMATOLOGIQUES AVENE	/	/	/	/	/
Evening Slots  18:00-19:30	Session Code		SAT117	SAT118	SAT119	SAT120	SAT121							
	Presentation: 18:00-19:00	/	AbbVie	Sanofi Genzyme & Regeneron	Janssen	Galderma	Boehringer Ingelheim International GmbH	/	/	/	/	/	/	/
Extended Presentation: 19:00-19:30														



## VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE

### Satellite Symposia

**Saturday 02 October 2021**

Access restricted to Health Care Professionals Only

Access Open to All

Room name	Room 1	Room 2	Room 3	Room 4	Room 5	Room 6	Room 7	Room 8	Room 9	Room 10	Room 11	Room 12	Room 13
Capacity	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited
<b>Saturday 02 October 2021</b>													
Morning Slots 1  08:30-09:30	Session Code  Presentation: 08:30-09:30												
Lunch Slots  13:00-14:00	Session Code  Presentation: 13:00-14:00												
Evening Slots  18:00-19:30	Session Code  Presentation: 18:00-19:00  Extended Presentation: 19:00-19:30		SAT151  Boehringer Ingelheim International GmbH										



## VIRTUAL INDUSTRY SESSION PROGRAMMES AT A GLANCE

### Industry HUB

Access restricted to Health Care Professionals Only       Access Open to All

Thursday 30 September 2021			Friday 01 October 2021			Saturday 02 October 2021		
Room Names	Room HUB 1	Room HUB 2	Location	Room HUB 1	Room HUB 2	Location	Room HUB 1	Room HUB 2
Capacities	100 pax	200 pax	Capacity	100 pax	200 pax	Capacity	100 pax	200 pax
Session Code		HUB2.01	Session Code	HUB1.08	HUB2.08	Session Code		
Presentation: 09:00-09:45		Galderma	Presentation: 09:00-09:45	L'Oréal - La Roche-Posay	Galderma	Presentation: 09:00-09:45		
Session Code		HUB2.02	Session Code	HUB1.09		Session Code		HUB2.16
Presentation: 10:00-10:45		PIERRE FABRE DERMATOLOGIE	Presentation: 10:00-10:45	siHealth		Presentation: 10:00-10:45		UCB
Session Code	HUB1.03	HUB2.03	Session Code		HUB2.10	Session Code		
Presentation: 11:15-12:00	L'Oréal Paris	LEO Pharma	Presentation: 11:15-12:00		LEO Pharma	Presentation: 11:15-12:00		
Session Code	HUB1.04	HUB2.04	Session Code	HUB1.11	HUB2.11	Session Code		HUB2.18
Presentation: 12:15-13:00	Amgen	UCB	Presentation: 12:15-13:00	Vichy Laboratoires	Janssen	Presentation: 12:15-13:00		Galderma
13:00 - 14:00 break								
Session Code	HUB1.05	HUB2.05	Session Code	HUB1.12	HUB2.12	Session Code		HUB2.19
Presentation: 14:00-14:45	Sofwave	Almirall	Presentation: 14:00-14:45	Pfizer	LEO Pharma	Presentation: 14:00-14:45		LEO Pharma
Session Code	HUB1.06	HUB2.06	Session Code	HUB1.13	HUB2.13	Session Code		
Presentation: 15:00-15:45	L'Oréal - La Roche-Posay	Janssen	Presentation: 15:00-15:45	CeraVe	LEO Pharma	Presentation: 15:00-15:45		
Session Code	HUB1.07	HUB2.07	Session Code	HUB1.14	HUB2.14	Session Code		
Presentation: 16:00-16:45	CeraVe	UCB	Presentation: 16:00-16:45	British Association of Dermatologists (BAD)	UCB	Presentation: 16:00-16:45		



## INDUSTRY SESSION PROGRAMME AND FACULTY IN PARTICULAR

The Industry session organiser is solely responsible for keeping any of its industry sessions activities compliant with all relevant laws and regulations. EADV is not involved with or has any control over the content, quality, organisation, operation, scientific integrity of the activity and materials provided by the industries. EADV is not involved in the selection of speakers, moderators and other faculty.

## ACCESS TO INDUSTRY SESSIONS AND REGULATIONS RELATED TO INDUSTRY ACTIVITIES

As a multidisciplinary audience will be attending the EADV 30th Congress, please make sure to select the right category, Healthcare Professionals (HCPs) and Non-Healthcare Professionals (NON-HCPs), during the registration process.

Access to any industry sessions where data or research of prescription medicines is presented will be limited exclusively to Healthcare Professionals (HCPs) only. For more information please download the [Austrian Ethical Rules](#).

Industry Session organisers may limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry session.



Wednesday 29 September 2021

SATELLITE SYMPOSIA

SAT 10	Vichy Laboratoires (Open to all)
Stressed skin: from acute exposome impact to skin care innovation	
10:00 - 11:00	Room: 1
Chair:	Thierry Passeron (Nice, France)
SAT 10.01	<b>10:00 A new rising concern among patients: stressed skin</b> Thierry Passeron (Nice, France)
SAT 10.02	<b>10:07 Probiotic fractions, 25 years of research and proven efficacy in restoring and regenerating the skin barrier and skin immunological-antioxidant defenses</b> Frédérique Labatut (Chevilly la rue, France)
SAT 10.03	<b>10:12 Skin stressed by UV and pollution: can we prevent it?</b> Giuseppe Valacchi (Ferrara, Italy)
SAT 10.04	<b>10:22 Probiotic fractions proven efficacy in the following dermatological indications:</b> <b>-Adjvant to topical retinoids for skin ageing</b> Jerry Tan (Ontario, Canada) <b>-Rosacea clinical signs and symptoms</b> Enzo Berardesca (Milano, Italy) <b>-Facial COVID-19 mask dermatitis</b> Markus Reinholtz (München, Germany)
SAT 10.05	<b>10:42 Conclusion</b> Jerry Tan (Ontario, Canada)
SAT 10.06	<b>10:47 Q&amp;A</b> Thierry Passeron (Nice, France)





Wednesday 29 September 2021

SATELLITE SYMPOSIA

**SAT 23**

		<b>Eucerin by BEIERSDORF (HCP only)</b>
		<b>Acne leaves its marks: Spot the problem – Face the challenge</b>
11:30 - 12:30		Room: 1
Chair:		Shirin Keyhanian (Hamburg, Germany)
SAT 23.01	11:30	<b><i>Introduction</i></b>
		Shirin Keyhanian (Hamburg, Germany)
SAT 23.02	11:35	<b><i>Acne and acne-related post-inflammatory hyperpigmentation – quo vadis?</i></b>
		Vincenzo Bettoli (Ferrara, Italy)
SAT 23.03	11:50	<b><i>Acne and acne-related post-inflammatory hyperpigmentation – a physical and emotional burden</i></b>
		Alison Layton (Harrogate, United Kingdom)
SAT 23.04	12:05	<b><i>Maximizing the power of patented Thiamidol with innovation tailored for acne-prone skin: Reduction &amp; prevention of blemishes and post-acne marks for improved quality of life</i></b>
		Julia Gallinger (Hamburg, Germany)
SAT 23.05	12:20	<b><i>Discussion, Q &amp; A</i></b>
		All – panel discussion



**SAT 24**

		<b>Bella Aurora Labs (HCP only)</b>
		<b>MIA-inhibitors technology: a new option in managing vitiligo</b>
11:30 - 12:30		Room: 2
Chair:		Agustín Alomar Muntañola (Barcelona, Spain)
SAT 24.01	11:30	<b><i>Vitiligo: pathogenesis and current treatment options.</i></b>
		Agustín Alomar Muntañola (Barcelona, Spain)
SAT 24.02	11:50	<b><i>The role of MIA protein in the pathogenesis of vitiligo and clinical efficacy of the MIA inhibitor technology.</i></b>
		Matteo Bordignon (Padova, Italy)
SAT 24.03	12:20	<b><i>A new development in vitiligo</i></b>
		Marta Bajona Roig (Santa Coloma de Cervelló, Spain)
SAT 24.04	12:25	<b><i>Round Table and Q&amp;A</i></b>
		Marta Bajona Roig (Santa Coloma de Cervelló, Spain)





Wednesday 29 September 2021

SATELLITE SYMPOSIA

SAT 25		<b>Amryt Pharma DAC (Open to all)</b>
		<b>Epidermolysis Bullosa: The Depth of Disease and Improving Patient Outcomes</b>
11:30 - 12:30		Room: 3
Chair:		Eli Sprecher (Tel Aviv, Israel)
SAT 25.01	11:30	<b>Introduction</b>
		Eli Sprecher (Tel Aviv, Israel)
SAT 25.02	11:35	<b>The visible challenge and natural history</b>
		Danielle Greenblatt (London, United Kingdom)
SAT 25.03	11:50	<b>Inflammation and pathophysiology: What lies beneath</b>
		Leena Bruckner-Tuderman (Freiburg, Germany)
SAT 25.04	12:05	<b>Improving outcomes for patients: Future developments</b>
		Eli Sprecher (Tel Aviv, Israel)
SAT 25.05	12:20	<b>Panel discussion</b>
		Eli Sprecher (Tel Aviv, Israel)
		Leena Bruckner-Tuderman (Freiburg, Germany)
		Danielle Greenblatt (London, United Kingdom)
SAT 25.06	12:30	<b>Summary and close</b>
		Eli Sprecher (Tel Aviv, Israel)



SAT 36		<b>Novartis (HCP only)</b>
		<b>The complete management of psoriatic disease in a COVID world</b>
13:00 - 14:00		Room: 1
Chair:		Diamant Thaçi (Luebeck, Germany)
SAT 36.01	13:00	<b>Introduction</b>
		Diamant Thaçi (Luebeck, Germany)
SAT 36.02	13:05	<b>What really matters to the patient?</b>
		April Armstrong (Los Angeles, CA, United States)
SAT 36.03	13:15	<b>Thinking beyond the skin in psoriatic disease</b>
		Diamant Thaçi (Luebeck, Germany)
SAT 36.04	13:30	<b>Safety matters: making informed treatment decisions in a post-pandemic world</b>
		Christopher Griffiths (Manchester, United Kingdom)
SAT 36.05	13:40	<b>Live Panel discussion and Q&amp;A</b>
		All – panel discussion
SAT 36.06	13:55	<b>Closing remarks</b>
		Diamant Thaçi (Luebeck, Germany)





Wednesday 29 September 2021

SATELLITE SYMPOSIA

SAT 37

Janssen (HCP only)

**Diving deep: harnessing the potential of the IL-23 pathway**

13:00 - 14:00

Room: 2

Chairs:

Jo Lambert (Ghent, Belgium)

Bruce Strober (New Haven, United States)



SAT 37.01

13:00 **Welcome and introduction**

Jo Lambert (Ghent, Belgium)

SAT 37.02

13:05 **Perspectives from dermatology: the potential of IL-23 inhibition for long-term disease remission**

Bruce Strober (New Haven, United States)

SAT 37.03

13:20 **Perspectives from rheumatology: going under and beyond the skin**

Daniel Aletaha (Vienna, Austria)

SAT 37.04

13:35 **Putting the pieces together: looking for best value in psoriasis**

Jo Lambert (Ghent, Belgium)

SAT 37.04

13:50 **Panel discussion and Q&A**

Jo Lambert (Ghent, Belgium)

Bruce Strober (New Haven, United States)

Daniel Aletaha (Vienna, Austria)

SAT 37.06

13:55 **Closing remarks**

Bruce Strober (New Haven, United States)



Wednesday 29 September 2021

SATELLITE SYMPOSIA

SAT 38

L'Oréal - La Roche-Posay (Open to all)

**REVOLUTION IN PHOTOPROTECTION:**

- **How to recommend and adapt photoprotection according to skin phototype and dermatoses?**
- **Innovation on UVA: launching a new filter**

13:00 - 14:00

Room: 3

Chair:

Thierry Passeron (Nice, France)

**LA ROCHE POSAY**  
LABORATOIRE DERMATOLOGIQUE

SAT 38.01

**13:00 Introduction**

Thierry Passeron (Nice, France)

SAT 38.02

**13:05 Skin phototypes**

Sergio Schalka (Sao Paulo, Brazil)

SAT 38.03

**13:10 Photoaging**

Jean Krutmann (Düsseldorf, Germany)

SAT 38.04

**13:15 Skin cancers**

Brigitte Dréno (Nantes, France)

SAT 38.05

**13:20 Photodermatoses**

Henry Lim (Detroit, United States)

SAT 38.06

**13:25 Pigmentary disorders**

Thierry Passeron (Nice, France)

SAT 38.07

**13:30 Skin inflammatory disorders**

Jorge Ocampo Candiani (Monterrey, Mexico)

SAT 38.08

**13:35 Going further on uva: an even more complete protection**

Martin Josso (Paris, France)

SAT 38.09

**13:50 Q&A**

Thierry Passeron (Nice, France)



**Wednesday 29 September 2021**

**SATELLITE SYMPOSIA**

<b>SAT 39</b>	<b>Sanofi Genzyme &amp; Regeneron (Open to all)</b> <b>How Multidisciplinary Teams Improve Communication and Care in the Management of Atopic Dermatitis: Findings from the Atopic Dermatitis Quality of Care Initiative</b>	 <b>Quality of Care in AD</b>
13:00 - 14:00	Room: 4	
Chair:	Eric Simpson (Portland, United States)	
SAT 39.01	<b>13:00 Overview of Multidisciplinary Teams in the Atopic Dermatitis Quality of Care Initiative</b> Eric Simpson (Portland, United States)	
SAT 39.02	<b>13:10 Outcomes of cross-specialty collaboration in treatment of AD: Patients</b> Ketty Peris (Rome, Italy)	
SAT 39.03	<b>13:25 Outcomes of cross-specialty collaboration in treatment of AD: HCPs</b> Marjolein de Bruin-Weller (Utrecht, Netherlands)	
SAT 39.04	<b>13:40 Multidisciplinary Teams: Case Studies from International Centers</b> Eric Simpson (Portland, United States)	
SAT 39.05	<b>13:55 Discussion and Final Questions</b> Eric Simpson (Portland, United States) Ketty Peris (Rome, Italy) Marjolein de Bruin-Weller (Utrecht, Netherlands)	
<b>SAT 40</b>	<b>Lilly (HCP only)</b> <b>Bringing Clinical Trial Data To Life- 1 Year Of Olumiant (Baricitinib) Experience in Atopic Dermatitis Clinical Practice</b>	
14:30 - 15:30	Room: 10	
Chair:	Thomas Bieber (Bonn, Germany)	
SAT 40.01	<b>14:30 Introduction</b> Thomas Bieber (Bonn, Germany)	
SAT 40.02	<b>14:45 Translating clinical trial data into clinical practice</b> Thomas Bieber (Bonn, Germany)	
SAT 40.03	<b>15:00 Flexible patient- happy patient, what matters during long term management</b> Audrey Nosbaum (Lyon, France)	
SAT 40.04	<b>15:15 Lessons learnt from Rheumatology</b> Torsten Witte (Hannover, Germany)	
SAT 40.05	<b>15:25 Q&amp;A session</b> All – panel discussion	
SAT 40.06	<b>15:35 Wrap-up</b> Thomas Bieber (Bonn, Germany)	



Wednesday 29 September 2021

SATELLITE SYMPOSIA

SAT 41	CeraVe (Open to all) <b>Addressing Acne Medication-Induced Barrier Dysfunction with Adjunctive Therapy</b>
14:30 - 15:30	Room: 11 Chair: Dr. Zoe Draelos (High Point, United States) Prof. Brigitte Dreno (Nantes, France)
SAT 41.01	<b>14:30 Addressing Acne Medication-Induced Barrier Dysfunction with Adjunctive Therapy</b> Dr. Zoe Draelos (High Point, United States) Prof. Brigitte Dreno (Nantes, France)
SAT 41.02	<b>15:15 Live Q&amp;A</b> Dr. Zoe Draelos (High Point, United States) Prof. Brigitte Dreno (Nantes, France)



SAT 42	<b>Bristol Myers Squibb (HCP only, no industry participants)</b> <b>The TYK/JAK Family and Psoriasis Pathology</b>
14:30 - 15:30	Room: 12 Chair: Jo Lambert (Ghent, Belgium)
SAT 42.01	<b>14:30 A Molecular View of the Pathophysiology of Psoriasis</b> Jo Lambert (Ghent, Belgium)
SAT 42.02	<b>14:50 Differentiating TYK/JAK Family Members</b> Andrew Alexis (New York, United States)
SAT 42.03	<b>15:10 Clinical Data for TYK2 and JAK1,2,3 Inhibitors in Psoriasis</b> Matthias Augustin (Hamburg, Germany)





Wednesday 29 September 2021

SATELLITE SYMPOSIA

SAT 44

Amgen (HCP only)

**Telemedicine, treatment, and evidence: How can we provide the best treatment for patients with moderate psoriasis?**

15:45 - 16:45

Room: 10

Chair:

Matthias Augustin (Hamburg, Germany)



SAT 44.01

15:45 **Welcome and introduction**

Matthias Augustin (Hamburg, Germany)

SAT 44.02

15:55 **What are the unique needs and perspectives of patients with moderate psoriasis?**

Kave Shams (Leeds, United Kingdom)

SAT 44.03

16:05 **How could telemedicine improve the patient experience in moderate psoriasis?**

Alexander Zink (Munich, Germany)

SAT 44.04

16:15 **How can specific manifestations of PsO affect patient QoL?**

Kave Shams (Leeds, United Kingdom)

SAT 44.05

16:25 **How can RWE complement clinical trial data when selecting the most appropriate treatment for patients with moderate PsO?**

Matthias Augustin (Hamburg, Germany)

SAT 44.06

16:35 **Panel discussion with live Q&A**

All – panel discussion

SAT 44.07

16:40 **Summary and close: What is the future for PsO?**

Matthias Augustin (Hamburg, Germany)



Wednesday 29 September 2021

SATELLITE SYMPOSIA

SAT 51		<b>Sanofi Genzyme &amp; Regeneron (Open to all)</b> <b>Addressing the full impact of AD through the perspectives of kids and teens, caregivers and physicians: Key findings from the AD-GAP survey</b>	<b>SANOFI GENZYME</b>  <b>REGENERON</b>
17:00-18:30		Room: 4	
Chair:		Korey Capozza (Santa Barbara, United States)	
SAT 51.01	17:00	<b><i>More than skin deep: Introducing the AD-GAP survey</i></b> Korey Capozza (Santa Barbara, United States)	
SAT 51.02	17:10	<b><i>Addressing the full impact of AD</i></b> Amy Paller (Chicago, United States)	
SAT 51.03	17:25	<b><i>Living in the now with AD: Panel Discussion</i></b> Korey Capozza (Santa Barbara, United States) Amy Paller (Chicago, United States) Stephan Weidinger (Kiel, Germany) Mark Tang (Singapore, Singapore) Andrew Pink (London, United Kingdom)	
SAT 51.04	18:10	<b><i>Q&amp;A</i></b> Korey Capozza (Santa Barbara, United States) Amy Paller (Chicago, United States) Stephan Weidinger (Kiel, Germany) Mark Tang (Singapore, Singapore) Andrew Pink (London, United Kingdom)	
SAT 51.05	18:25	<b><i>Meeting Close</i></b> Korey Capozza (Santa Barbara, United States)	



Wednesday 29 September 2021

SATELLITE SYMPOSIA

SAT 57		<b>Sanofi Genzyme &amp; Regeneron (HCP only)</b> <b>Clinical Importance of Type 2 Inflammation in Dermatoses and Challenges in the Management of Atopic Dermatitis in the Pandemic Era</b>	SANOFI GENZYME  REGENERON
17:00 - 18:00		Room: 1	
Chair:		Emma Guttman-Yassky (New York, United States)	
SAT 57.01	17:00	<b><i>Introduction</i></b> Emma Guttman-Yassky (New York, United States)	
SAT 57.02	17:02	<b><i>Type 2 Inflammation in Atopic Dermatitis and Other Dermatologic Diseases</i></b> Patrick Brunner (Vienna, Austria)	
SAT 57.03	17:12	<b><i>Systemic Therapy in Patients with Atopic Dermatitis</i></b> April Armstrong (Los Angeles, United States)	
SAT 57.04	17:27	<b><i>Impact of COVID-19 on the Assessment and Treatment of Atopic Dermatitis</i></b> Emma Guttman-Yassky (New York, United States)	
SAT 57.05	17:47	<b><i>Live Q&amp;A with audience</i></b> All – panel discussion	
SAT 58		<b>Sanofi Genzyme &amp; Regeneron (Open to all)</b> <b>Addressing the Unmet Needs in Pemphigus</b>	SANOFI GENZYME  REGENERON
17:00 - 18:00		Room: 2	
Chair:		Dedee Murrell (Kogarah, Australia)	
SAT 58.01	17:00	<b><i>Introduction</i></b> Dedee Murrell (Kogarah, Australia)	
SAT 58.02	17:05	<b><i>Pathophysiology, clinical presentation and burden</i></b> Pascal Joly (Rouen Cedex, France)	
SAT 58.03	17:20	<b><i>Current management and unmet needs</i></b> Victoria Werth (Philadelphia, United States)	
SAT 58.04	17:35	<b><i>Emerging therapies</i></b> Dedee Murrell (Kogarah, Australia)	
SAT 58.05	17:50	<b><i>Live Q&amp;A</i></b> All – panel discussion	



Wednesday 29 September 2021

SATELLITE SYMPOSIA

SAT 59                    Medscape – Supported by an independent educational grant from Janssen (HCP only)  
Exploring New Frontiers in Atopic Dermatitis

17:00 - 18:30            Room: 3

Chair:                    Emma Guttman-Yassky (New York, United States)



SAT 59.01                17:00            ***Unmet needs in atopic dermatitis***

Kilian Eyerich (Munich, Germany)

SAT 59.02                17:10            ***AD pathophysiology and role of IL-1 $\alpha$  in AD***

Emma Guttman-Yassky (New York, United States)

SAT 59.03                17:25            ***Overview of therapeutic targets in AD***

Alan Irvine (Dublin, Ireland)

SAT 59.05                17:40            ***IL-1 $\alpha$  in other dermatologic conditions***

Errol Prens (Rotterdam, the Netherlands)

SAT 59.06                17:50            ***Panel Discussion***

All – panel discussion



Thursday 30 September 2021

SATELLITE SYMPOSIA

SAT 61		Galderma (Open to all)	GALDERMA
		<b>Paediatric Atopic Dermatitis: Current Developments</b>	
08:30 - 09:30		Room: 1	
Chair:		Krzysztof Piotrowski (Vevey, Switzerland)	
SAT 61.01	08:30	<b><i>Paediatric Dermatitis – what's new in 2021?</i></b>	
		Adelaide Hebert (Houston, United States)	
SAT 61.02	08:50	<b><i>Is it possible to prevent atopic dermatitis? Randomized control study of high risk babies</i></b>	
		Mark Koh (Singapore, Singapore)	
SAT 61.03	09:05	<b><i>Multidisciplinary management of children with atopic dermatitis, including psychological treatment</i></b>	
		Mark Koh (Singapore, Singapore)	
SAT 61.04	09:20	<b>Q&amp;A</b>	
		Krzysztof Piotrowski (Vevey, Switzerland)	
SAT 62		Almirall (HCP only)	
		<b>Tailoring topical psoriasis treatments to patients' needs and expectations</b>	
08:30 - 09:30		Room: 2	
Chair:		Peter Van de Kerkhof (Nijmegen, Netherlands)	
SAT 62.01	08:30	<b><i>Tailoring topical psoriasis treatments to patients' needs and expectations. Welcome and introductions.</i></b>	
		Peter Van de Kerkhof (Nijmegen, Netherlands)	
SAT 62.02	08:40	<b><i>The role of topical therapies along the psoriasis patient journey</i></b>	
		Andreas Pinter (Frankfurt am Main, Germany)	
SAT 62.03	08:55	<b><i>Engaging psoriasis patients in adherence (and outcomes) to topical treatments</i></b>	
		Anthony Bewley (London, United Kingdom)	
SAT 62.04	09:10	<b><i>Questions and answers discussion</i></b>	
		All – panel discussion	



Thursday 30 September 2021

SATELLITE SYMPOSIA

SAT 63

**Incyte Biosciences International Sàrl (Open to all)**

**Looking through the lens: an emerging future for vitiligo patients.**

08:30 - 09:30

Room: 3

Chair:

Khaled Ezzedine (Paris, France)



SAT 63.01

**08:30 Welcome and introductions**

Khaled Ezzedine (Paris, France)

SAT 63.02

**08:34 The disease mechanisms driving vitiligo**

Mauro Picardo (Rome, Italy)

SAT 63.03

**08:52 The unmet needs of patients with vitiligo; how should they be measured?**

Nanja van Geel (Heusden, Belgium)

SAT 63.04

**09:10 Current and future clinical research in vitiligo**

Khaled Ezzedine (Paris, France)

SAT 63.05

**09:28 Concluding remarks and meeting close**

Khaled Ezzedine (Paris, France)

SAT 64

**Medscape – Supported by an independent educational grant from Lilly. (HCP only)**



08:30-09:30

Room: 4

Chair:

Brett King (New Haven, United States)

SAT 64.01

**08:30 Welcome and Introductions**

Brett King (New Haven, United States)

SAT 64.02

**08:31 The Impact of Hair Disorders: Understanding a Patient's Journey**

Antonella Tosti (Miami, United States)

SAT 64.03

**08:50 Diagnosis and Assessment of Hair Disorders**

Lidia Rudnicka (Warsaw, Poland)

SAT 64.04

**09:05 The Immunopathogenesis and Management of Hair Disorders**

Brett King (New Haven, United States)

SAT 64.05

**09:20 Q&A**

All – panel discussion



Thursday 30 September 2021

SATELLITE SYMPOSIA

SAT 74	Lilly (HCP only)
	<b>What new data tell us – a fresh look into Nail Psoriasis management</b>
13:00 - 14:00	Room: 1
Chair:	Alexander Egeberg (Copenhagen, Denmark)
SAT 74.01	<b>13:00 Introduction</b> Alexander Egeberg (Copenhagen, Denmark)
SAT 74.02	<b>13:05 Clinical Presentation and Burden of Nail Psoriasis</b> Julia-Tatjana Maul (Zürich, Switzerland)
SAT 74.03	<b>13:20 Deciphering the role of Nail Psoriasis in Psoriatic Disease Progression</b> Frank Behrens (Frankfurt am Main, Germany)
SAT 74.04	<b>13:35 Treatment of Nail Psoriasis: Choosing the Right Biologic</b> Alexander Egeberg (Copenhagen, Denmark)
SAT 74.05	<b>13:50 Q&amp;A session</b> All – panel discussion
SAT 75	<b>Sanofi Genzyme &amp; Regeneron (Open to all)</b> <b>Unlocking the potential of immuno-oncology in advanced basal cell carcinoma</b>
13:00 - 14:00	Room: 2
Chair:	Dirk Schadendorf (Essen, Germany)
SAT 75.01	<b>13:00 Welcome and opening remarks</b> • <b>Introductions</b> • <b>History of immunotherapy in NMSC</b> Dirk Schadendorf (Essen, Germany)
SAT 75.02	<b>13:05 Current treatment landscape in advanced BCC</b> Salvador Martin-Algarra (Pamplona, Spain)
SAT 75.03	<b>13:20 Treatment paradigm and emerging approaches in advanced BCC</b> Dirk Schadendorf (Essen, Germany)
SAT 75.04	<b>13:35 Clinical implication of emerging Immunotherapy for advanced BCC</b> Christoph Hoeller (Vienna, Austria)
SAT 75.05	<b>13:50 Ask the faculty and concluding remarks</b> All – panel discussion





Thursday 30 September 2021

SATELLITE SYMPOSIA

**SAT 76**

**AbbVie** (HCP only)

**Discovering tomorrow's treatment advances in Dermatology**

13:00 - 14:00

Room: 3

Chair: Kilian Eyerich (Stockholm, Sweden)

SAT 76.01 13:00 **Welcome and introduction**

Kilian Eyerich (Stockholm, Sweden)

SAT 76.02 13:15 **Innovation in Dermatology: The journey so far...**

Kilian Eyerich (Stockholm, Sweden)

SAT 76.03 13:20 **Innovation in Dermatology: How did we get here?**

Bradford McRae (Worcester, United States)

SAT 76.04 13:35 **Innovation in Dermatology: What next!**

Heath Guay (Worcester, United States)

SAT 76.05 13:50 **Summary and close**

Kilian Eyerich (Stockholm, Sweden)

**abbvie**

**SAT 77**

**Medscape – Supported by an independent educational grant from**

**UCB Pharma, Inc.** (HCP only)

**Challenges and Opportunities in the Management of Psoriasis: The Evolving Treatment Landscape**

**Medscape<sup>®</sup>**  
EDUCATION GLOBAL

13:00 - 14:00

Room: 4

Chair: Richard Warren (Manchester, United Kingdom)

SAT 77.01 13:00 **Welcome and Introductions**

Richard Warren (Manchester, United Kingdom)

SAT 77.02 13:02 **Challenges in the Optimization of Care of Patients With Psoriasis**

Mark Lebwohl (New York, United States)

SAT 77.03 13:18 **Impact of Psoriasis on Patients**

Caitriona Ryan (Dublin, Ireland)

SAT 77.04 13:34 **Biologic Therapies for Moderate to Severe Psoriasis**

Richard Warren (Manchester, United Kingdom)

SAT 77.05 13:50 **Panel Discussion**

All – panel discussion



Thursday 30 September 2021

SATELLITE SYMPOSIA

SAT 78

Pfizer (HCP only)

**How can we address varying patient needs in Atopic Dermatitis: learnings from systemic JAK Inhibitors' clinical trial outcomes.**

13:00 - 14:00

Room: 5

Chair:

Andreas Wollenberg (Munich, Germany)



SAT 78.01

13:00 **Welcome and Review of AD, current treatment guidelines and the JAK/STAT pathway in AD**

Andreas Wollenberg (Munich, Germany)

SAT 78.02

13:15 **Clinical Profiles: Characterization of Systemic JAK inhibitors From the Molecule to the Clinic**

Mette Deleuran (Aarhus, Denmark)

SAT 78.03

13:35 **Going Deeper: Trials Designed to Explore Practical Questions**

Marjolein de Bruin-Weller (Utrecht, Netherlands)

SAT 78.04

13:55 **Live Q&A**

All - panel discussion

SAT 79

LEO Pharma (HCP only)

**A New Biologic Targeting IL-13 in The Age of Disruption in Atopic Dermatitis**

13:00 - 14:00

Room: 6

Chair:

Kristian Reich (Hamburg, Germany)



SAT 79.01

13:00 **A New Biologic Targeting IL-13 in The Age of Disruption in Atopic Dermatitis**

Kristian Reich (Hamburg, Germany)

Andreas Wollenberg (Munich, Germany)

Jacob Thyssen (Copenhagen, Denmark)

Marjolein Bruin-Weller (Utrecht, Netherlands)

Jonathan Silverberg (Washington, United States)



Thursday 30 September 2021

SATELLITE SYMPOSIA

SAT 80	Galderma (HCP only) <b>Personalising Acne: Consensus of Experts to optimise acne management</b>		GALDERMA
13:00 - 14:00	Room: 7		
Chair:	Alison Layton (Harrogate, United Kingdom)		
SAT 80.01	13:00	<b>Welcome</b> Alison Layton (Harrogate, United Kingdom)	
SAT 80.02	13:05	<b>Highlights on current unmet needs in acne care</b> Alison Layton (Harrogate, United Kingdom)	
SAT 80.03	13:15	<b>Improving future acne care through a structured expert consensus</b> Linda Stein Gold (Michigan, United States)	
SAT 80.04	13:25	<b>Personalised Acne Care Pathway: A practical solution for longitudinal management</b> Jerry Tan (Ontario, Canada)	
SAT 80.05	13:35	<b>Live Q&amp;A</b> All - panel discussion	
SAT 80.06	13:58	<b>Conclusion</b> Alison Layton (Harrogate, United Kingdom)	
SAT 82	<b>Bristol Myers Squibb (HCP only, no industry participants)</b> <b>Oral Therapies: Their Profiles and Roles in the Psoriasis Treatment Landscape</b>		Bristol Myers Squibb™
13:00 - 14:00	Room: 9		
Chair:	Wolf Henning Boehncke (Geneva, Switzerland)		
SAT 82.01	13:00	<b>Unmet Needs in Psoriasis</b> Curdin Conrad (Geneva, Switzerland)	
SAT 82.02	13:20	<b>Mechanisms of Action for Oral Agents</b> Wolf Henning Boehncke (Geneva, Switzerland)	
SAT 82.03	13:40	<b>Clinical Data for Oral Agents in Psoriasis</b> Bruce Strober (Southington, United States)	



Thursday 30 September 2021

SATELLITE SYMPOSIA

SAT 83

**Medthority (HCP only)**

**Biologic heroes: Are you keeping up with the rapidly evolving treatment landscape for paediatric psoriasis?**

18:00 - 19:00

Room: 2

Chair:

Amy Paller (Chicago, IL, United States)



SAT 83.01

**18:00 Welcome and introduction**

Amy Paller (Chicago, IL, United States)

SAT 83.02

**18:05 How are new treatments addressing the unmet needs in paediatric psoriasis?**

Amy Paller (Chicago, IL, United States)

SAT 83.03

**18:20 Differentiating between the emerging approved biologic treatments for paediatric psoriasis**

Matthias Augustin (Hamburg, Germany)

SAT 83.04

**18:35 Achieving long-term clearance in paediatric psoriasis**

Marieke Seyger (Nijmegen, Netherlands)

SAT 83.05

**18:50 Live Q&A and Panel Discussion**

All – panel discussion

SAT 84

**AbbVie (HCP only)**

**Are we experiencing a revolution in AD management?**

18:00 - 19:30

Room: 3

Chair:

Melinda Gooderham (Peterborough, Canada)



SAT 84.01

**18:00 Welcome and introduction**

Melinda Gooderham (Peterborough, Canada)

SAT 84.02

**18:05 Unmet needs in AD: where are we today?**

Marjolein de Bruin-Weller (Utrecht, Netherlands)

SAT 84.03

**18:35 Breaking boundaries in AD management**

Melinda Gooderham (Peterborough, Canada)

SAT 84.04

**18:55 New frontiers in AD treatment**

Jonathan Silverberg (Washington DC, United States)

SAT 84.05

**19:25 Summary and conclusions**

Melinda Gooderham (Peterborough, Canada)



Thursday 30 September 2021

SATELLITE SYMPOSIA

**SAT 85**

		<b>Sanofi Genzyme (HCP only)</b>
		<b>Taking the Long View on Disease Control in Atopic Dermatitis</b>
18:00 - 19:30		Room: 4
Chair:		Thomas Bieber (Bonn, Germany)
SAT 85.01	18:00	<b>Introduction</b> Thomas Bieber (Bonn, Germany)
SAT 85.02	18:03	<b>Long-term Disease Control in Atopic Dermatitis</b> Stephan Weidinger (Kiel, Germany)
SAT 85.03	18:27	<b>Real-world Perspectives on Long-term Biologic Therapy for Atopic Dermatitis</b> Thomas Bieber (Bonn, Germany)
SAT 85.04	18:51	<b>The Evolving Therapeutic Landscape for Patients with Moderate-to-Severe Atopic Dermatitis</b> Jonathan Silverberg (Washington, United States)
SAT 85.05	19:15	<b>Live Q&amp;A with audience</b> All – panel discussion

SANOFI GENZYME REGENERON

**SAT 86**

		<b>Med Learning Group on behalf of Regeneron Pharmaceuticals, Inc and Sanofi Genzyme (Open to all)</b>
		<b>A Whiteboard View of Systemic Management of Advanced Basal Cell Carcinoma: Going Beyond Aberrant Pathway Signaling to Activate the Immune Response</b>
18:00 - 19:30		Room: 5
Chair:		Aimilios Lallas (Thessaloniki, Greece)
SAT 86.01	18:00	<b>Pathogenesis of Advanced Basal Cell Skin Cancer</b> Aimilios Lallas (Thessaloniki, Greece)
SAT 86.02	18:20	<b>Epidemiology of Basal Cell Carcinoma</b> Aimilios Lallas (Thessaloniki, Greece)
SAT 86.03	18:45	<b>NCCN Practice Guidelines in Locally Advanced/Metastatic Disease</b> Anokhi Jambusaria-Pahlajani (Austin, United States)
SAT 86.04	19:05	<b>Emerging Immune Checkpoint Inhibition for Systemic Disease</b> Anokhi Jambusaria-Pahlajani (Austin, United States)
SAT 86.05	19:15	<b>Conclusions/Question-and Answers</b> All – panel discussion





**Thursday 30 September 2021**

**SATELLITE SYMPOSIA**

**SAT 87**

**Janssen (HCP only)**  
**The dermatologist's guide to the clearance of the skin**  
 18:00 - 19:15 Room: 6  
 Chairs: Kilian Eyerich (Stockholm, Sweden)  
 Melinda Gooderham (Peterborough, ON, Canada)  
 Brian Kirby (Dublin, Ireland)



SAT 87.01	18:00	<b>Welcome and introduction</b> Brian Kirby (Dublin, Ireland)
SAT 87.02	18:05	<b>Don't panic! New strategy for established treatment on the horizon</b> Kilian Eyerich (Munich, Germany)
SAT 87.03	18:20	<b>The answer to the ultimate question: long-term clinical and registry data</b> Brian Kirby (Dublin, Ireland)
SAT 87.04	18:35	<b>And another thing... looking beyond the skin in psoriasis patients</b> Melinda Gooderham (Peterborough, ON, Canada)
SAT 87.05	18:50	<b>Panel discussion and Q&amp;A</b> All – panel discussion
SAT 87.06	19:10	<b>So long, and thanks for all the questions</b> Kilian Eyerich (Munich, Germany)

**SAT 88**

**Galderma (HCP only)**  
**Prurigo Nodularis: From Patient to Pathway**  
 18:00 - 19:30 Room: 7  
 Chair: Gil Yosipovitch (Miami, United States)

**GALDERMA**

SAT 88.01	18:00	<b>Welcome and introduction by Chairperson</b> Gil Yosipovitch (Miami, United States)
SAT 88.02	18:03	<b>The Multi-Dimensional Impact of Prurigo Nodularis</b> Gil Yosipovitch (Miami, United States)
SAT 88.03	18:17	<b>Illuminating the Role of IL-31: The Neuro-Immune Cytokine</b> Martin Steinhoff (Doha, Qatar)
SAT 88.04	18:31	<b>Investigational Product - Nemolizumab: The Next Generation Therapy in Phase 3 for PN</b> Sonja Ständer (Münster, Germany)
SAT 88.05	18:45	<b>Live Q&amp;A With All Speakers and Symposium Closing Address</b> Gil Yosipovitch (Miami, United States) Martin Steinhoff (Doha, Qatar) Sonja Ständer (Münster, Germany)



Thursday 30 September 2021

SATELLITE SYMPOSIA

SAT 89

Almirall (HCP only)

A novel approach in the management of patients with Actinic Keratosis

18:00 - 19:30

Room: 8

Chair:

Rolf-Markus Szeimies (Recklinghausen, Germany)



SAT 89.01

18:00 **Welcome and introduction**

Rolf-Markus Szeimies (Recklinghausen, Germany)

SAT 89.02

18:05 **Clinical data landscape in Actinic Keratosis**

Rolf-Markus Szeimies (Recklinghausen, Germany)

SAT 89.03

18:20 **MoA of current treatments in Actinic Keratosis**

Yolanda Gilaberte (Zaragoza, Spain)

SAT 89.04

18:35 **Clinical cases discussion**

Edward Lain (Austin, United States)

SAT 89.05

18:50 **Q&A**

All – panel discussion



Thursday 30 September 2021

**INDUSTRY HUB**

**HUB 1.03**

L'Oréal Paris (Open to all)

**NEW TRENDS IN HYALURONIC ACID: The Dermatologist's gold standard in fillers becomes the new must-have for moisture and plump in cosmetic routines**

11:15-12:00

Room: HUB 1

Chair:

Sabine Zenker (Munich, Germany)

**L'ORÉAL PARIS**

HUB 1.03.01

**11:15      The science of Hyaluronic Acid: mechanism of action in the skin**

Sabine Zenker (Munich, Germany)

HUB 1.03.02

**11:24      Hyaluronic Acid: what's new in professional procedures: microneedling, fractional lasers, healing**

Maria Teresa Luverà (Livorno, Italy)

HUB 1.03.03

**11:29      The place of Hyaluronic Acid in women cosmetic routines: clinical cases**

Cristina Eguren (Madrid, Spain)

HUB 1.03.04

**11:34      The benefits that cosmetic Hyaluronic Acid can bring to our younger patients**

Ophelia Veraitch (London, United Kingdom)

HUB 1.03.05

**11:39      Hyaluronic Acid, a pillar in anti-aging routines for all women**

Dr Laurence Walon (Brussels, Belgium)

HUB 1.03.06

**11:44      Myths & Truths about Hyaluronic Acid**

Christian Tran (Paris, France)

HUB 1.03.07

**11:49      Clinical evaluation of plump and its evolution with age: A new method and standardized atlas**

Frédéric Flament (Paris, France)

HUB 1.03.08

**11:54      Serum formulation with 1.5% of pure HA: Clinical studies and results after 1 week, 4 weeks, 6 weeks**

Elisabeth Bouhadana (Paris, France)

**HUB 1.04**

Amgen (HCP only)

**Unveiling the patient with moderate plaque psoriasis patient: Expanding existing knowledge with real-world data**

12:15-13:00

Room: HUB 1

Chair:

Paolo Gisondi (Verona, Italy)

**AMGEN®**

HUB 1.04.01

**12:15      Unveiling the patient with moderate plaque psoriasis: Expanding existing knowledge with real-world data**

Paolo Gisondi (Verona, Italy)

HUB 1.04.02

**12:45      Audience Q&A**

Paolo Gisondi (Verona, Italy)



Thursday 30 September 2021

**INDUSTRY HUB**

**HUB 1.05**

**Sofwave** (Open to all)

**Sofwave, The Newest in Ultrasound Technology. A review of clinical studies, technology and a demonstration. Synchronous Ultrasound Parallel Beam Technology SUPERB for skin tightening.**

14:00-14:45

Room: HUB 1

Chair:

Michael Gold (Nashville, United States)



HUB 1.05.01

14:00

**Sofwave, The Newest in Ultrasound Technology. A review of clinical studies, technology and a demonstration. Synchronous Ultrasound Parallel Beam Technology SUPERB for skin tightening.**

Michael Gold (Nashville, United States)

**HUB 1.06**

**L'Oréal - La Roche-Posay** (Open to all)

**Managing skin side effects from cancer treatments: where do we stand?**

15:00-15:45

Room: HUB 1

Chairs:

Brigitte Dréno (Nantes, France)

Mario Lacouture (NYC, United States)



HUB 1.06.01

15:00

**Prophylaxis and management of skin toxicities by the dermatologist**

Brigitte Dréno (Nantes, France)

HUB 1.06.02

15:10

**How can supportive care improve quality of life**

Mario Lacouture (NYC, United States)

HUB 1.06.03

15:40

**Q&A**

Brigitte Dréno (Nantes, France)



**Thursday 30 September 2021**

## INDUSTRY HUB

### HUB 1.07

		<b>CeraVe (Open to all)</b>
		<b>Restoring Lipid Structure Organization Leads to Improved Patient Outcomes in Dry, Eczema-Prone Skin</b>
16:00-16:45		Room: HUB 1
Chair:		Michael J. Cork (Hope Valley, United Kingdom)
HUB 1.07.01	16:00	<b>Restoring Lipid Structure Organization Leads to Improved Patient Outcomes in Dry, Eczema-Prone Skin</b>
		Michael J. Cork (Hope Valley, United Kingdom)
HUB 1.07.02	16:35	<b>Live Q &amp; A</b>
		Michael J. Cork (Hope Valley, United Kingdom)



### HUB 2.01


		<b>Galderma (Open to all)</b>
		<b>The many faces of Maskne – a new skin burden / an upcoming disease</b>
09:00-09:45		Room: HUB 2
Chair:		Markus Reinholtz (Munich, Germany)
HUB 2.01.01	09:00	<b>Introduction</b>
		Markus Reinholtz (Munich, Germany)
HUB 2.01.02	09:02	<b>Polling Part 1</b>
		Markus Reinholtz (Munich, Germany)
HUB 2.01.03	09:04	<b>Maskne an upcoming disease</b>
		Markus Reinholtz (Munich, Germany)
HUB 2.01.04	09:14	<b>Q&amp;A Part 1</b>
		Markus Reinholtz (Munich, Germany)
HUB 2.01.05	09:17	<b>Polling Part 2</b>
		Anne-Charlotte Kuna (Munich, Germany)
HUB 2.01.06	09:19	<b>Maskne the Munich experience</b>
		Anne-Charlotte Kuna (Munich, Germany)
HUB 2.01.07	09:27	<b>Q&amp;A Part 2</b>
		Anne-Charlotte Kuna (Munich, Germany)
HUB 2.01.08	09:30	<b>Polling Part 3</b>
		Markus Reinholtz (Munich, Germany)
HUB 2.01.09	09:32	<b>Therapeutic Options for Maskne</b>
		Markus Reinholtz (Munich, Germany)
HUB 2.01.10	09:42	<b>Q&amp;A Part 3 &amp; Conclusion</b>
		Markus Reinholtz (Munich, Germany)

**GALDERMA**



Thursday 30 September 2021

## INDUSTRY HUB

HUB 2.02	PIERRE FABRE DERMATOLOGIE (HCP only)	Pierre Fabre DERMATOLOGIE
10:00-10:45	<b>Beyond the results of treatments, look for actinic keratosis severity</b> Room: HUB 2	
HUB 2.02.01	<b>10:00 Welcome and introduction</b> Alain Delarue (Lavaur, France)	
HUB 2.02.02	<b>10:03 What are AK patients' expectations when treating a field cancerization?</b> Maria Concetta Farnoli (L'Aquila, Italy)	
HUB 2.02.03	<b>10:13 Network meta-analysis: a tool for finding a way in the jungle of treatments for actinic keratosis</b> Khaled Ezzedine (Bordeaux, France)	
HUB 2.02.04	<b>10:25 When treating a field cancerization, consider AK severity</b> Eggert Stockfleth (Bochum, Germany)	
HUB 2.02.05	<b>10:40 Questions-Answers</b> Alain Delarue (Lavaur, France) Maria Concetta Farnoli (L'Aquila, Italy) Khaled Ezzedine (Bordeaux, France) Eggert Stockfleth (Bochum, Germany)	
HUB 2.03	<b>LEO Pharma (HCP only)</b> <b>Navigating through an era of targeted therapies for atopic dermatitis</b>	
11:15-12:00	Room: HUB 2	
HUB 2.03.01	<b>11:15 Welcome and introduction</b> Mette Deleuran (Aarhus, Denmark)	
HUB 2.03.02	<b>11:20 Where do we stand on the road to targeted therapies for atopic dermatitis?</b> Mette Deleuran (Aarhus, Denmark)	
HUB 2.03.03	<b>11:30 Tailored treatments based on patient expectations</b> Alan Irvine (Dublin, Ireland)	
HUB 2.03.04	<b>11:40 Making the therapeutic choice</b> Alan Irvine (Dublin, Ireland)	
HUB 2.03.05	<b>11:50 Q&amp;A</b> Speakers & audience	



Thursday 30 September 2021

**INDUSTRY HUB**

**HUB 2.04**

UCB (HCP only)

**Nominations are in: The psoriasis pathogenesis awards**

12:15-13:00

Room: HUB 2

Chair:

Wolf-Henning Boehncke (Geneva Switzerland)



HUB 2.04.01 12:15 **Welcome and Introduction**

Wolf-Henning Boehncke (Geneva, Switzerland)

HUB 2.04.02 12:18 **A crucial contribution: The IL-23/IL-17 axis in psoriasis**

Wolf-Henning Boehncke (Geneva, Switzerland)

HUB 2.04.03 12:30 **A clear focus: Targeting the key drivers of disease**

Lluís Puig (Barcelona, Spain)

HUB 2.04.04 12:40 **A long view: How will clear skin benefit patients?**

Menno de Rie (Amsterdam, The Netherlands)

HUB 2.04.05 12:49 **Panel discussion and questions from the audience**

Wolf-Henning Boehncke (Geneva Switzerland)

Lluís Puig (Barcelona, Spain)

Menno de Rie (Amsterdam, The Netherlands)

HUB 2.04.06 12:59 **Conclusions and meeting closes**

Wolf-Henning Boehncke (Geneva, Switzerland)



Thursday 30 September 2021

**INDUSTRY HUB**

**HUB 2.05**

**Almirall (HCP only)**

**Advancing the standard of care in AD: can we be more specific?**

14:00-14:45

Room: HUB 2

Chair:

Jacob Thyssen (Copenhagen, Denmark)



HUB 2.05.01    14:00

**Welcome and introductions**

Jacob Thyssen (Copenhagen, Denmark)

HUB 2.05.02    14:01

**Burden of atopic dermatitis for patients – really understanding patient unmet needs**

Jacob Thyssen (Copenhagen, Denmark)

HUB 2.05.03    14:05

**Pathophysiology of the disease and potential therapeutical targets**

Stephan Weidinger (Kiel, Germany).

HUB 2.05.04    14:08

**Strategy of blocking IL4/IL13 – first biologic available and big advancement, but there are still unmet needs**

Jacob Thyssen (Copenhagen, Denmark)

Stephan Weidinger (Kiel, Germany).

HUB 2.05.05    14:18

**Strategy of blocking IL13 alone – might it be enough to control atopic dermatitis?**

Jacob Thyssen (Copenhagen, Denmark)

Stephan Weidinger (Kiel, Germany).

HUB 2.05.06    14:30

**Questions and answers - discussion**

Jacob Thyssen (Copenhagen, Denmark)

Stephan Weidinger (Kiel, Germany).



**Thursday 30 September 2021**

## INDUSTRY HUB

### HUB 2.06

Janssen (HCP only)

**Remember to forget me: the disease modifying potential of targeting tissue-resident memory cells in psoriasis**

15:00-15:45

Room: HUB 2

Chair:

James Krueger (New York, United States)



HUB 2.06.01 15:00

**Welcome and introduction**

Tiago R. Matos (Amsterdam, Netherlands)

HUB 2.06.02 15:05

**Looking behind the scenes – disease memory in psoriasis**

James Krueger (New York, United States)

HUB 2.06.03 15:20

**Moving towards remission – long-term treatment in psoriasis**

Tiago R. Matos (Amsterdam, Netherlands)

HUB 2.06.04 15:35

**Q&A**

James Krueger (New York, United States)

Tiago R. Matos (Amsterdam, Netherlands)

HUB 2.06.05 15:40

**Conclusion and close**

James Krueger (New York, United States)

### HUB 2.07

UCB (HCP only)

**The XX-factor: Does a patient's sex matter in psoriasis?**

16:00-16:45

Room: HUB 2

Chair:

Cæcilie Bachdal Johansen (Copenhagen, Denmark)



HUB 2.07.01 16:00

**Welcome, housekeeping and introduction**

Cæcilie Bachdal Johansen (Copenhagen, Denmark)

HUB 2.07.02 16:05

**Perspectives in favour of considering patient sex**

Nina Magnolo (Münster, Germany)

HUB 2.07.03 16:17

**Teaching perspectives in areas not considering patient sex**

Álvaro González-Cantero (Madrid, Spain)

HUB 2.07.04 16:29

**Live Q&A and polling**

Cæcilie Bachdal Johansen (Copenhagen, Denmark)

Nina Magnolo (Münster, Germany)

Álvaro González - Cantero (Madrid, Spain)

HUB 2.07.05 16:37

**Closing remarks**

Cæcilie Bachdal Johansen (Copenhagen, Denmark)



Friday 01 October 2021

SATELLITE SYMPOSIA

SAT 95	Galderma (Open to all) <b>Advancing Sensitive Skin: Diagnosis, Morphological Traits and Epidemiology</b>		GALDERMA
08:30-09:30	Room: 1		
Chair:	Giovanni Pellacani (Rome, Italy)		
SAT 95.01	08:30	<b><i>Diagnosis of sensitive skin - is there an ideal tool?</i></b>	
		Laurent Misery (Brest, France)	
SAT 95.02	08:45	<b><i>Discovery of morphological traits to differentiate sensitive skin from non-sensitive skin</i></b>	
		Giovanni Pellacani (Rome, Italy)	
SAT 95.03	09:00	<b><i>Proposal for Cut-off Scores for Sensitive Skin on Sensitive Scale-10</i></b>	
		Emilie Brenaut (Brest, France)	
SAT 95.04	09:10	<b><i>Profiling of sensitive skin using clinical data, Real life data meta-analysis</i></b>	
		Gwendoline Baruchet (Vevey, Switzerland)	
SAT 95.05	09:20	<b><i>Live Q&amp;A</i></b>	
		Giovanni Pellacani (Rome, Italy)	
SAT 108	Novartis (HCP only)	Targeting complete CSU control: current state of the art and future perspectives	
13:00-14:00	Room: 1		
Chair:	Ana Maria Giménez-Arnau (Barcelona, Spain)		
SAT 108.01	13:00	<b><i>Welcome and introductions</i></b>	
		Ana Maria Giménez-Arnau (Barcelona, Spain)	
SAT 108.02	13:05	<b><i>The patient journey in CSU: The challenges we face</i></b>	
		Ana Maria Giménez-Arnau (Barcelona, Spain)	
SAT 108.03	13:15	<b><i>Optimizing patient outcomes in CSU: Could new biologics help achieve this?</i></b>	
		Romi Saini (Baltimore, United States)	
SAT 108.04	13:30	<b><i>Exploring novel pathways in the journey to complete CSU control</i></b>	
		John Reed (Oxford, United Kingdom)	
SAT 108.05	13:45	<b><i>Live Q&amp;A</i></b>	
		All – panel discussion	
SAT 108.06	13:55	<b><i>Summary and closing remarks</i></b>	
		Ana Maria Giménez-Arnau (Barcelona, Spain)	





Friday 01 October 2021

SATELLITE SYMPOSIA

**SAT 109** **AbbVie** (HCP only)

**Demystifying JAK inhibitors: what do I need to know?**

13:00-14:00 Room: 2

Chair: Alan Irvine (Dublin, Ireland)

SAT 109.01 13:00 **Welcome and introduction**

Alan Irvine (Dublin, Ireland)

SAT 109.02 13:05 **Why JAK inhibitors for atopic dermatitis**

Jacob Thyssen (Copenhagen, Denmark)

SAT 109.03 13:20 **Who can benefit from JAK inhibitors**

Eric Simpson (Portland, United States)

SAT 109.04 13:35 **How do I use JAK inhibitors?**

Alan Irvine (Dublin, Ireland)

SAT 109.05 13:55 **Summary and Conclusions**

Alan Irvine (Dublin, Ireland)

**abbvie**

**SAT 110** **Sanofi Genzyme & Regeneron** (HCP only)

**Planning For The Future: It's Time For Long-Term Control In Atopic**

**Dermatitis** SANOFI GENZYME REGENERON

13:00-14:00 Room: 3

Chairs: Melinda Gooderham (Peterborough, Canada)  
Michael Cork (Sheffield, United Kingdom)

SAT 110.01 13:00 **Introduction**

Vivienne Parry (Oxfordshire, United Kingdom)

SAT 110.02 13:05 **Exploring the burden of AD in pediatric and adult patients [video]**

Michael Cork (Sheffield, United Kingdom)

SAT 110.03 13:10 **Burden of AD in pediatric and adult patients**

Michael Cork (Sheffield, United Kingdom)

SAT 110.04 13:20 **Moderated discussion**

All – panel discussion

SAT 110.05 13:30 **Treatment selection for patients with AD**

Melinda Gooderham (Peterborough, Canada)

SAT 110.06 13:40 **Moderated discussion**

All – panel discussion

SAT 110.07 13:50 **Q&A with audience**

All – panel discussion



**Friday 01 October 2021**

### SATELLITE SYMPOSIA

<b>SAT 111</b>		<b>UCB (HCP only)</b>
		<b>Awards night! New advances in treating psoriasis</b>
13:00-14:00		Room: 4
Chair:		Richard Warren (Manchester, United Kingdom)
SAT 111.01	13:00	<b>Welcome and Introduction</b> Richard Warren (Manchester, United Kingdom)
SAT 111.02	13:03	<b>Overall picture: Targeting key drivers of psoriasis</b> Richard Warren (Manchester, United Kingdom)
SAT 111.03	13:18	<b>Lasting contribution: Achieving a rapid response that lasts</b> Diamant Thaci (Lübeck, Germany)
SAT 111.04	13:33	<b>Meaningful improvement: Improving quality of life for patients with psoriasis</b> April Armstrong (Los Angeles, United States)
SAT 111.05	13:48	<b>Panel discussion and questions from the audience</b> Richard Warren (Manchester, United Kingdom) Diamant Thaci (Lübeck, Germany) April Armstrong (Los Angeles, United States)
SAT 111.06	13:58	<b>Conclusions and meeting close</b> Richard Warren (Manchester, United Kingdom)



<b>SAT 112</b>		<b>Pfizer (HCP only)</b>
		<b>Navigating the new world of dermatology</b>
13:00-14:00		Room: 5
SAT 112.01	13:00	<b>Introduction</b> Mark Porter (Cheltenham, United Kingdom)
SAT 112.02	13:05	<b>Decoding the updated road map: from patient to treatment - Part I: Immunological concepts in dermatology</b> Ali Jabbari (Iowa City, United States)
SAT 112.03	13:15	<b>Decoding the updated road map: from patient to treatment - Part II: Matching treatment to disease</b> Thomas Bieber (Bonn, Germany)
SAT 112.04	13:30	<b>Plotting your patient's course with practical decision making</b> Mark Porter (Cheltenham, United Kingdom) Ali Jabbari (Iowa City, United States) Thomas Bieber (Bonn, Germany)
SAT 112.05	13:55	<b>A medical education programme for dermatology</b> Mark Porter (Cheltenham, United Kingdom)





Friday 01 October 2021

SATELLITE SYMPOSIA

SAT 113		Galderma (HCP only)	GALDERMA
13:00-14:00		<b>Moderate to Severe Atopic Dermatitis – a disease of the skin and beyond</b>	
Chair:		Room: 6	
		Diamant Thaçi (Lübeck, Germany)	
SAT 113.01	13:00	<b>Welcome and Introduction by the Chair</b>	Diamant Thaçi (Lübeck, Germany)
SAT 113.02	13:02	<b>Atopic Dermatitis burden beyond the skin</b>	Jonathan Silverberg (Washington, United States)
SAT 113.03	13:16	<b>IL-31: the central neuro-immune cytokine in AD</b>	Bernhard Homey (Düsseldorf, Germany)
SAT 113.04	13:30	<b>Blocking IL-31 signalling in AD – the nemolizumab emerging clinical data</b>	Diamant Thaçi (Lübeck, Germany)
SAT 113.05	13:44	<b>Live panel discussion and Q&amp;A</b>	All Faculty
SAT 114		Almirall (HCP only)	 almirall
13:00-14:00		<b>Are you wasting your time getting to PASI100? Come and listen to the brain fight with the skin!</b>	
Chair:		Room: 7	
		Stefano Piaserico (Padova, Italy)	
SAT 114.01	13:00	<b>Introduction</b>	Stefano Piaserico (Padova, Italy)
SAT 114.02	13:05	<b>Round 1: The dermatologist vs the behavioral scientist - who is better at managing our patients?</b>	Stefano Piaserico (Padova, Italy)
		Jordi Quoidbach (Barcelona, Spain)	
SAT 114.03	13:35	<b>How can we apply patient wellbeing to psoriasis? Introducing the POSITIVE study: Patient-reported wellbeing using tildrakizumab in a live setting</b>	Ulrich Mrowietz (Kiel, Germany)
SAT 114.04	13:55	<b>Closing</b>	Stefano Piaserico (Padova, Italy)



Friday 01 October 2021

SATELLITE SYMPOSIA

SAT 115

LABORATOIRES DERMATOLOGIQUES AVENE (Open to all)

"Light and shadows of blue light and sunscreens - a dermatological, environmental and patients perspective"

13:00-14:00

Room: 8

Chair:

Eggert Stockfleth (Bochum, Germany)

SAT 115.01 13:00

***Introduction***

Ariadna Ortiz Brugués (Lavaur, France)

SAT 115.02 13:03

***Looking at blue light: new perspectives in sunscreens***

Eggert Stockfleth (Bochum, Germany)

SAT 115.03 13:23

***Fate of UV filters in the marine environment: from portioning to ecotoxicity***

Philippe Lebaron (Paris, France)

SAT 115.04 13:38

***Photoprotection and self skin examination to improve melanoma survival***

Enrique Barba (Barcelona, Spain)

SAT 115.05 13:48

***Discussion***

Eggert Stockfleth (Bochum, Germany)

Philippe Lebaron (Paris, France)

Enrique Barba (Barcelona, Spain)

Ariadna Ortiz Brugués (Lavaur, France)

SAT 115.06 13:55

***Q & A***

Eggert Stockfleth (Bochum, Germany)

Philippe Lebaron (Paris, France)

Enrique Barba (Barcelona, Spain)

EAU THERMALE

Avène



**Friday 01 October 2021**

**SATELLITE SYMPOSIA**

**SAT 117**

**AbbVie (HCP only)**

**Psoriasis management: Reducing the long-term impact of psoriasis**

*"Commit to clear: changing lives for the long term"*

18:00-19:30

Room: 2

Chair:

Richard Warren (Manchester, United Kingdom)

**abbvie**

SAT 117.01      18:00

**Welcome and introduction**

Richard Warren (Manchester, United Kingdom)

SAT 117.02      18:05

**Why commit to clear?**

April Armstrong (Los Angeles, United States)

SAT 117.03      18:20

**Best chance for clear**

Richard Warren (Manchester, United Kingdom)

SAT 117.04      18:40

**A clear difference**

Brian Kirby (Dublin, Ireland)

SAT 117.05      18:55

**Changing lives for the long term**

Richard Warren (Manchester, United Kingdom)

April Armstrong (Los Angeles, United States)

Brian Kirby (Dublin, Ireland)

SAT 117.06      19:25

**Summary and close**

Richard Warren (Manchester, United Kingdom)



**Friday 01 October 2021**

### SATELLITE SYMPOSIA

#### SAT 118

		<b>Sanofi Genzyme &amp; Regeneron (HCP only)</b>
		<b>Targeting Better Disease Control in Pediatric Patients with Atopic Dermatitis</b>
18:00-19:30		Room: 3
Chair:		Amy Paller (Chicago, United States)
SAT 118.01	<b>18:00</b>	<b><i>Introduction</i></b>
		Amy Paller (Chicago, United States)
SAT 118.02	<b>18:05</b>	<b><i>Aspects of Disease Burden in Pediatric Patients with Atopic Dermatitis</i></b>
		Ulrike Blume-Peytavi (Berlin, Germany)
SAT 118.03	<b>18:29</b>	<b><i>Managing Atopic Dermatitis in Pediatric Patients</i></b>
		Amy Paller (Chicago, United States)
SAT 118.04	<b>18:53</b>	<b><i>Expanding Treatment Options for the Pediatric Patient</i></b>
		Larry Eichenfield (San Diego, United States)
SAT 118.05	<b>19:17</b>	<b><i>Live Q&amp;A with audience</i></b>
		All – panel discussion

SANOFI GENZYME REGENERON

#### SAT 119

		<b>Janssen (HCP only)</b>
		<b>The art of joint forces: crafting PsA care for dermatologists</b>
18:00-19:15		Room: 4
Chairs:		Alexander Egeberg (Copenhagen, Denmark)
		Laura Savage (Leeds, United Kingdom)
		Joseph Merola (Boston, United States)
SAT 119.01	<b>18:00</b>	<b><i>Welcome and introduction</i></b>
		Alexander Egeberg (Copenhagen, Denmark)
SAT 119.02	<b>18:05</b>	<b><i>Dermatologists' toolbox for the early detection of PsA</i></b>
		Alexander Egeberg (Copenhagen, Denmark)
SAT 119.03	<b>18:20</b>	<b><i>The nuts and bolts of PsA therapy</i></b>
		Laura Savage (Leeds, United Kingdom)
SAT 119.04	<b>18:35</b>	<b><i>Carving the road to lasting peace: designing effective PsA treatment in daily practice</i></b>
		Joseph Merola (Boston, United States)
SAT 119.05	<b>18:50</b>	<b><i>Painting harmony: tips and pitfalls from combined clinics</i></b>
		Laura Savage (Leeds, United Kingdom)
SAT 119.06	<b>19:05</b>	<b><i>Q&amp;A and closing</i></b>
		Alexander Egeberg (Copenhagen, Denmark)

**Janssen** **Immunology**  
PHARMACEUTICAL COMPANIES OF



**Friday 01 October 2021**

#### SATELLITE SYMPOSIA

SAT 120			GALDERMA
<b>18:00-19:30</b>			
Chair:			James Q. Del Rosso (Las Vegas, United States)
SAT 120.01	<b>18:00</b>	<b>Welcome and Introduction</b>	
		James Q. Del Rosso (Las Vegas, United States)	
SAT 120.02	<b>18:05</b>	<b>Papulopustular Rosacea: who are our patients</b>	
		Hilary E. Baldwin (New Jersey, United States)	
SAT 120.03	<b>18:15</b>	<b>The systemic treatment spectrum: current landscape</b>	
		James Q. Del Rosso (Las Vegas, United States)	
SAT 120.04	<b>18:30</b>	<b>Getting the best out of rosacea treatment: a need for a new expert consensus?</b>	
		Martin Schaller (Tübingen, Germany)	
SAT 120.05	<b>18:40</b>	<b>Live panel discussion and Q&amp;A</b>	
		All faculty	
SAT 120.06	<b>18:55</b>	<b>Conclusion</b>	
		James Q. Del Rosso (Las Vegas, United States)	
SAT 121			
<b>18:00-19:30</b>			
Chair:			Diamant Thaçi (Luebeck, Germany)
SAT 121.01	<b>18:00</b>	<b>Welcome &amp; Introduction</b>	
		Diamant Thaçi (Luebeck, Germany)	
SAT 121.02	<b>18:05</b>	<b>United: Bridging the GaPP</b>	
		Sicily Mburu (Bromma, Sweden)	
SAT 121.03	<b>18:15</b>	<b>Exploring the GaPPs in Everyday Practice</b>	
		Melinda Gooderham (Peterborough, ON, Canada)	
SAT 121.04	<b>18:35</b>	<b>GaPPs in the 40-year Therapeutic Path Trudge</b>	
		Luis Puig (Barcelona, Spain)	
SAT 121.05	<b>18:50</b>	<b>Closing GaPPs: Evolving the Treatment of GPP</b>	
		David Burden (Glasgow, United Kingdom)	
SAT 121.06	<b>19:10</b>	<b>Panel discussion</b>	
		All – panel discussion	





Friday 01 October 2021

## INDUSTRY HUB

### HUB 1.08

L'Oréal - La Roche-Posay (Open to all)

**Atopic dermatitis: new technology to act fast during flare ups at all ages**

09:00-09:45 Room: HUB 1

Chair: Bernhard Homey (Düsseldorf, Germany)



HUB 1.08.01 09:00 **Atopic dermatitis and microbiome: where do we stand?**

Bernhard Homey (Düsseldorf, Germany)

HUB 1.08.02 09:10 **Introducing Endobioma: inspired by the phage technology**

Anne-Laure Demessant (Paris, France)

HUB 1.08.03 09:40 **Q&A**

Anne-Laure Demessant (Paris, France)

### HUB 1.09

siHealth (HCP only)

**Experiences of Actinic Keratosis (AK) daylight PDT treatment supported by the SmartPDT digital system**

10:00-10:45 Room: HUB 1

Chair: Emilio Simeone (Oxford, United Kingdom)



HUB 1.09.01 10:00 **Introduction**

Emilio Simeone (Oxford, United Kingdom)

HUB 1.09.02 10:10 **Daylight PDT AK lesion precision dosimetry : the new dPDT challenge**

Ewan Eadie (Dundee, United Kingdom)

HUB 1.09.03 10:25 **SmartPDT: real-word evidences of a digitally supported home self-administered dPDT of AK**

Yolanda Gilaberte (Zaragoza, Spain)

HUB 1.09.04 10:40 **Q&A Session**

Emilio Simeone (Oxford, United Kingdom)



Friday 01 October 2021

## INDUSTRY HUB

### HUB 1.11

	Vichy Laboratoires (Open to all)
	<b>Dandruff and seborrheic dermatitis: from the microbiome science to clinical evidence</b>
12:15-13:00	Room: HUB 1
Chair:	Sergio Vaño-Galván (Madrid, Spain)
HUB 1.11.01	<b>12:15 Dandruff and seborrheic dermatitis: the central role of scalp microbiome</b>
	Sergio Vaño-Galván (Madrid, Spain)
HUB 1.11.02	<b>12:30 Dercos ds solution proven efficacy: from microbiome impact to clinical study results</b>
	Eugenia Capetta (Buenos Aires, Argentina)
HUB 1.11.03	<b>12:45 Q&amp;A</b>
	Sergio Vaño-Galván (Madrid, Spain)



### HUB 1.12

	Pfizer (HCP only)
	<b>Dermatology and diversity: 3 short talks about the future we all want to create</b>
14:00-14:45	Room: HUB 1
Chair:	Seemal Desai (Dallas, United States)
HUB 1.12.01	<b>14:00 Opening and intro to our equity platform</b>
	Seemal Desai (Dallas, United States)
HUB 1.12.02	<b>14:10 The significance of skin: Some cultural context</b>
	Nina Jablonski (Philadelphia, United States)
HUB 1.12.03	<b>14:20 Diversity: a dermatological perspective</b>
	Seemal Desai (Dallas, United States)
HUB 1.12.04	<b>14:30 In my own skin</b>
	Natalie Ambersley (Hornchurch, United Kingdom)
HUB 1.12.05	<b>14:40 Closing: wrap up and invitation to visit the platform</b>
	Seemal Desai (Dallas, United States)





Friday 01 October 2021

**INDUSTRY HUB**

**HUB 1.13**

		<b>CeraVe (Open to all)</b>
		<b>Clinical Solutions for Chronic Drug-Induced Xerosis in Elderly Patients</b>
15:00-15:45		Room: HUB 1
Chair:		Federica Filippi (Bologna, Italy)
HUB 1.13.01	15:00	<b><i>Clinical Solutions for Chronic Drug-Induced Xerosis in Elderly Patients</i></b>
		Federica Filippi (Bologna, Italy)
HUB 1.13.02	15:35	<b><i>Live Q &amp; A</i></b>
		Federica Filippi (Bologna, Italy)



**HUB 1.14**

		<b>British Association of Dermatologists (BAD) (Open to all)</b>
		<b>SHD and CED – BAD journals</b>
16:00-16:45		Room: HUB 1
Chair:		George Millington (Norfolk, United Kingdom)
HUB 1.14.01	16:00	<b><i>Publishing to Skin Health and Disease: BAD's open access multidisciplinary journal</i></b>
		George Millington (Norfolk, United Kingdom)
		Ewan Langan (Lübeck, Germany)
HUB 1.14.02	16:20	<b><i>Q&amp;A</i></b>
		George Millington (Norfolk, United Kingdom)
		Ewan Langan (Lübeck, Germany)
HUB 1.14.03	16:30	<b><i>Clinical and Experimental Dermatology: BAD's education journal</i></b>
		Alexa Shipman (Portsmouth, United Kingdom)
HUB 1.14.04	16:40	<b><i>Q&amp;A</i></b>
		Alexa Shipman (Portsmouth, United Kingdom)





**Friday 01 October 2021**

## INDUSTRY HUB

### HUB 2.08

**Galderma (Open to all)**

**GALDERMA**

09:00-09:45

**Onychomycosis Update – Novel findings: Prevalence, epidemiology and topical Therapy**

Room: HUB 2

Chair:

Dieter Reinel (Hamburg, Germany)

HUB 2.08.01 09:00

**Introduction**

Dieter Reinel (Hamburg, Germany)

HUB 2.08.02 09.02

**Onychomycosis Update – Novel findings: Prevalence, epidemiology and topical Therapy**

Dieter Reinel (Hamburg, Germany)

HUB 2.08.03 09:40


**Q&A**

Dieter Reinel (Hamburg, Germany)

Schafiq Nabhani (Düsseldorf, Germany)

### HUB 2.10

**LEO Pharma (HCP only)**



**Explore the latest science and data of plaque psoriasis flare control with Cal/BD foam**

11:15-12:00

Room: HUB 2

Chair:

Anthony Bewley (London, United Kingdom)

HUB 2.10.01 11:15

**Welcome and introduction**

Presenter

HUB 2.10.02 11:20

**Key factors in treatment success in psoriasis with topical therapy**

Ahmad Jalili (Buochs, Switzerland)

HUB 2.10.03 11:25

**The science of flare control with Cal/BD foam**

Presenter

HUB 2.10.04 11:35

**Clinical update: QoL from the 4-week, open-label phase of PSO-LONG**

Ahmad Jalili (Buochs, Switzerland)

HUB 2.10.05 11:40

**Clinical update: Cal/BD foam: Impact in real-world clinical settings.**

Anthony Bewley (London, United Kingdom)

HUB 2.10.06 11:50

**Discussion: Practical implications for the topical treatment of patients with mild-to-moderate psoriasis**

Anthony Bewley (London, United Kingdom)

Ahmad Jalili (Buochs, Switzerland)



Friday 01 October 2021

## INDUSTRY HUB

### HUB 2.11

Janssen (HCP only)

**The road to safety: a clinical dialogue on the safety of biologics in psoriasis**

12:15-13:00 Room: HUB 2

Chairs: Kenneth Gordon (Milwaukee, United States)  
Elke de Jong (Nijmegen, Netherlands)

HUB 2.11.01 12:15 **Welcome and introduction**

Kenneth Gordon (Milwaukee, United States)

HUB 2.11.02 12:20 **Bringing peace to a body at war – IL-23 and IL-17 inhibitors, are they safe? A dialogue on clinical trial and real-world safety data**

Kenneth Gordon (Milwaukee, United States)  
Elke de Jong (Nijmegen, Netherlands)

HUB 2.11.03 12:30 **Q&A**

Kenneth Gordon (Milwaukee, United States)  
Elke de Jong (Nijmegen, Netherlands)

HUB 2.11.04 12:35 **A Balancing Act – immunosuppression and immune defence in psoriasis and psoriatic arthritis**

Kenneth Gordon (Milwaukee, United States)  
Elke de Jong (Nijmegen, Netherlands)

HUB 2.11.05 12:45 **Q&A**

Kenneth Gordon (Milwaukee, United States)  
Elke de Jong (Nijmegen, Netherlands)

HUB 2.11.06 12:55 **Conclusion and Close**

Elke de Jong (Nijmegen, Netherlands)

**Janssen** Immunology  
PHARMACEUTICAL COMPANIES OF Johnson & Johnson



Friday 01 October 2021

## INDUSTRY HUB

### HUB 2.12

LEO Pharma (HCP only)


**Long-term maintenance treatment of plaque psoriasis with Cal/BD foam. A new approach in topical therapy**

14:00-14:45

Room: HUB 2

Chair:

Linda Stein Gold (Detroit, United States)



HUB 2.12.01 14:00

**Welcome and introduction**

Presenter

HUB 2.12.02 14:05

**Why is a chronic condition like psoriasis often managed reactively and what challenges do patients face with this treatment approach? What is the expert view on using topical treatments in psoriasis over the long-term?**

Presenter

HUB 2.12.03 14:10

**Exploring data and benefits of long-term, proactive management of psoriasis over 52-weeks with Cal/BD foam**

Presenter

HUB 2.12.04 14:20

**Proactive management with Cal/BD foam in PSO-LONG: Efficacy and safety update.**

Michael Sticherling (Erlangen, Germany)

HUB 2.12.05 14:30

**Health-related quality of life improvements with long-term, proactive management using Cal/BD foam**

Linda Stein Gold (Detroit, United States)

HUB 2.12.06 14:35

**Round table discussion: What are the practical implications for long-term, proactive management of psoriasis with Cal/BD foam?**

Michael Sticherling (Erlangen, Germany)

Linda Stein Gold (Detroit, United States)



**Friday 01 October 2021**

## INDUSTRY HUB

### HUB 2.13

**LEO Pharma (HCP Only)**

**Adult Female Acne: Case Studies on Current Challenges and Lessons Learned**

15:00-15:45

Room: HUB 2

Chair:

Alison Layton (Harrogate, United Kingdom)



HUB 2.13.01 15:00

**Welcome**

Alison Layton (Harrogate, United Kingdom)

HUB 2.13.02 15:02

**Introduction to clinical characteristics of adult female acne**

Ediléia Bagatin (São Paulo, Brazil)

HUB 2.13.03 15:10

**Adult female acne: Case studies from UK**

Alison Layton (Harrogate, United Kingdom)

HUB 2.13.04 15:20

**Adult female acne: Case studies from Brazil**

Ediléia Bagatin (São Paulo, Brazil)

HUB 2.13.05 15:30

**LIVE Q&A**

Alison Layton (Harrogate, United Kingdom)

Ediléia Bagatin (São Paulo, Brazil)

### HUB 2.14

**UCB (HCP only)**

**Don't delay: Support women with psoriasis on their journey to motherhood**

16:00-16:45

Room: HUB 2

Chair:

Aikaterini Patsatsi (Thessaloniki, Greece)



HUB 2.14.01 16:00

**Welcome, housekeeping and introductions**

Aikaterini Patsatsi (Thessaloniki, Greece)

HUB 2.14.02 16:03

**Management of women with psoriasis: Shared decision making**

Annunziata Dattola (Rome, Italy)

HUB 2.14.03 16:13

**Management of women with psoriasis: a holistic view**

Aikaterini Patsatsi (Thessaloniki, Greece)

HUB 2.14.04 16:23

**Discussion: The MDT perspective in treating women with psoriasis**

Aikaterini Patsatsi (Thessaloniki, Greece)

Annunziata Dattola (Rome, Italy)

Aarthi Mohan (Bristol, United Kingdom)

HUB 2.14.05 16:35

**Live Q&A with audience**

Aikaterini Patsatsi (Thessaloniki, Greece)

Annunziata Dattola (Rome, Italy)

Aarthi Mohan (Bristol, United Kingdom)

HUB 2.14.06 16:43

**Closing remarks**

Aikaterini Patsatsi (Thessaloniki, Greece)



Saturday 02 October 2021

**SATELLITE SYMPOSIA**

**SAT 151**

**Boehringer Ingelheim International GmbH (HCP only)**  
**Don't Judge a Book by Its Cover: Uncovering the Role of Autoinflammation in Skin Disease**



18:00-19:30

Room: 2

Chair:

Georg Stingl (Vienna, Austria)

SAT 151.01      18:00      ***IL-36: A Novel Pathway in Inflammation***

Georg Stingl (Vienna, Austria)

SAT 151.02      18:10      ***A New-trophilic Chapter in Hidradenitis Suppurativa***

Errol Prens (Rotterdam, Netherlands)

SAT 151.03      18:30      ***Inflammatory Pathways and Patient Impact in Atopic Dermatitis***

Patrick Brunner (Vienna, Austria)

SAT 151.04      18:50      ***Exposing a Major Character in Pustular Forms of Psoriasis***

Hervé Bachéléz (Paris, France)

SAT 151.05      19:05      ***Wrapping Up the Loose Ends: IL-36 Inhibition in Inflammatory Skin Diseases***

Robert Bissonnette (Montreal, Canada)

SAT 151.06      19:20      ***Q&A Panel***

All – panel discussion



Saturday 02 October 2021

## INDUSTRY HUB

### HUB 2.16

UCB (HCP only)

**Let the celebrations begin: Giving patients the opportunity to take control of their psoriasis**

10:00-10:45 Room: HUB 2

Chair: Sandy McBride (London, United Kingdom)



HUB 2.16.01 10:00 **Welcome and Introduction**

Sandy McBride (London, United Kingdom)

HUB 2.16.02 10:03 **Who's celebrating? Introducing the patient**

Andreas Pinter (Frankfurt, Germany)

HUB 2.16.03 10:13 **Celebrating with style: Treat to target**

Sandy McBride (London, United Kingdom)

HUB 2.16.04 10:23 **Celebrating improvements: Aiming for clear skin**

Paolo Gisondi (Verona, Italy)

HUB 2.16.05 10:33 **Panel discussion and questions from the audience**

Sandy McBride (London, United Kingdom)

Andreas Pinter (Frankfurt, Germany)

Paolo Gisondi (Verona, Italy)

HUB 2.16.06 10:43 **Conclusions and meeting close**

Sandy McBride (London, United Kingdom)

### HUB 2.18

Galderma (HCP only)

GALDERMA

**Artificial daylight photodynamic therapy: Advancing actinic keratosis treatment**

12:15-13:00 Room: HUB 2

Chair: Rolf-Markus Szeimies (Recklinghausen, Germany)

HUB 2.18.01 12:15 **Welcome and Introduction**

Rolf-Markus Szeimies (Recklinghausen, Germany)

HUB 2.18.02 12:20 **Can daylight photodynamic therapy be performed indoors?**

Serge Mordon (Ascaïn, France)

HUB 2.18.03 12:30 **What is the clinical evidence of artificial daylight photodynamic therapy for actinic keratosis?**

Rolf-Markus Szeimies (Recklinghausen, Germany)

HUB 2.18.04 12:40 **Practical demonstration video**

Rolf-Markus Szeimies (Recklinghausen, Germany)

HUB 2.18.05 12:43 **Live panel discussion and Q&A**

All faculty

HUB 2.18.06 12:58 **Conclusion**

Rolf-Markus Szeimies (Recklinghausen, Germany)



Saturday 02 October 2021

**INDUSTRY HUB**

**HUB 2.19**

**LEO Pharma (HCP only)**


**Topical Antimicrobials: Data, Guidelines, and Real-Life Practice**

14:00-14:45

Room: HUB 2

Chair:

Diamant Thaçi (Lübeck, Germany)



HUB 2.19.01 14:00 **Welcome and introduction**

Diamant Thaçi (Lübeck, Germany)

HUB 2.19.0 14:05 **How topical antibiotics work and data from clinical trials**

Diamant Thaçi (Lübeck, Germany)

HUB 2.19.0 14:15 **An overview of topical antifungal treatments and their efficacy**

Stefano Veraldi (Milan, Italy)

HUB 2.19.0 14:25 **Guidelines, reviews, and treatment considerations**

Diamant Thaçi (Lübeck, Germany)

Stefano Veraldi (Milan, Italy)

HUB 2.19.0 14:35 **Panel discussion and Q&A**

Diamant Thaçi (Lübeck, Germany)

Stefano Veraldi (Milan, Italy)